Form 4: Interpace Biosciences CFO Receives Stock Grant

Sentiment:

Insider Transaction (Form 4)


Christopher Mccarthy, CFO & COO of Interpace Biosciences, Inc., reported multiple transactions in common stock on August 20, 2026.

Summary

  • Option exercise/conversion: acquired 277,009 Common Stock on August 20, 2026; holds 323,800 after (Direct).
  • Grant/award: acquired 554,018 Restricted Stock Units on August 20, 2026; holds 554,018 after (Direct).
  • Option exercise/conversion: disposed of 277,009 Restricted Stock Units on August 20, 2026; holds 277,009 after (Direct).
  • Grant/award: acquired 277,009 Stock Option (right to buy) on August 20, 2026; holds 277,009 after (Direct).

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as routine: the reported changes are grants, option exercises, tax withholding or similar administrative transactions, which carry limited directional signal.

Insider Transactions

Christopher Mccarthy — Officer (CFO & COO)

DateTransactionSecuritySharesPriceValueHeld After
2026-08-20Option exercise/conversionCommon Stock277,009——323,800
2026-08-20Grant/awardRestricted Stock Units554,018——554,018
2026-08-20Option exercise/conversionRestricted Stock Units277,009——277,009
2026-08-20Grant/awardStock Option (right to buy)277,009——277,009

Key Dates

DateDescription
2026-08-20Option exercise/conversion (277,009 shares)
2026-08-20Grant/award (554,018 shares)
2026-08-20Option exercise/conversion (277,009 shares)
2026-08-20Grant/award (277,009 shares)

Keywords

insider transaction, Form 4, IDXG, INTERPACE BIOSCIENCES, INC., neutral, Christopher Mccarthy

Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.